Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00198601
Other study ID # H.22.02.08.30.B1
Secondary ID
Status Completed
Phase Phase 4
First received September 12, 2005
Last updated April 18, 2018
Start date August 2003
Est. completion date July 2005

Study information

Verified date September 2005
Source Johns Hopkins Bloomberg School of Public Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine what dosage of gentamicin for use in one-time administration device (Uniject) is appropriate.


Description:

This study aims to verify dosages of gentamicin for use in Uniject, chosen based on a consideration of gentamicin pharmacokinetics, safety, efficacy, target population body weight, cost, feasibility and acceptability.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date July 2005
Est. primary completion date July 2005
Accepts healthy volunteers No
Gender All
Age group N/A to 28 Days
Eligibility Inclusion Criteria:

- infants with culture proven sepsis

- infants 2000-2499 at birth

- infants > 2500 gm at birth

- infants < 2000 gm at birth

- in study site areas: Pakistan, Bangladesh and India

Exclusion Criteria:

- infants w/o culture proven sepsis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gentamicin in Uniject Pre-filled syringe


Locations

Country Name City State
Bangladesh Dhaka Shishu Hospital Dhaka
India Neonatal Intensive Care Unit - Christian Vellore Medical Vellore
Pakistan Aga Khan Karachi

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins Bloomberg School of Public Health

Countries where clinical trial is conducted

Bangladesh,  India,  Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patients 2.0-2.24 kg high peak>12.0: 2/6 patients
Primary Low peak<4.0: none
Primary High trough > 2.0: 1/6 patients
Secondary Patients 2.5-3.0 kg
Secondary High peak>12.0: 2/14 patients
Secondary Low peak <4.0: none
Secondary High trough>2.0:2/14 patients
See also
  Status Clinical Trial Phase
Completed NCT04529421 - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting NCT00342589 - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Withdrawn NCT04217252 - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection N/A
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Withdrawn NCT02904434 - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting NCT02768454 - Antimicrobials Stewardship by Pharmacist N/A
Completed NCT02219776 - Decreasing Infection In Arthroscopic Shoulder Surgery N/A
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Recruiting NCT02098226 - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts N/A
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Completed NCT01434797 - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Terminated NCT01441206 - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants Phase 1
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A